Friday 6 November 2026 Export CAI’s income statement to Excel — free account

Caris Life Sciences,�Inc.

Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.

Revenue: +27.0%
EPS: −40.3%
Free cash flow: −140.2%
Total debt: +4.46%

Quarter to September 2026, against a year earlier

Insider buying

25.13 0.90 −3.46%

Follow CAI

Alert me

Market cap: $7.4B
P/E: 77.7×
Fwd P/E: 254×
Dividend yield: —
F-score: n/a
Altman Z: 3.55
Beneish M: −2.71
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Caris Life Sciences,�Inc. 8-K filed Oct 30, 2025

Period ended Oct 30, 2025 · Filed Oct 30, 2025 · accepted 4:20 PM ET · Document on sec.gov · Filing index

3.03 Material modification of shareholders' rights; 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov

Caris Life Sciences,�Inc. 8-K filed Oct 30, 2025

Stockrow Weekly